Copyright Reports & Markets. All rights reserved.

Global Neurogenetic Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Neurogenetic Testing by Type
    • 1.3.1 Overview: Global Neurogenetic Testing Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Neurogenetic Testing Consumption Value Market Share by Type in 2025
    • 1.3.3 Exome Sequencing
    • 1.3.4 Whole Genome Sequencing
    • 1.3.5 RNA Sequencing
    • 1.3.6 General DNA Testing
  • 1.4 Classification of Neurogenetic Testing by Disease Type
    • 1.4.1 Overview: Global Neurogenetic Testing Market Size by Disease Type: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Neurogenetic Testing Consumption Value Market Share by Disease Type in 2025
    • 1.4.3 Neurodegenerative Disorders
    • 1.4.4 Neuromuscular Disorders
    • 1.4.5 Epilepsy Disorders
    • 1.4.6 Neurodevelopmental Disorders
    • 1.4.7 Genetic Brain Disorders
  • 1.5 Classification of Neurogenetic Testing by Sample Type
    • 1.5.1 Overview: Global Neurogenetic Testing Market Size by Sample Type: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Neurogenetic Testing Consumption Value Market Share by Sample Type in 2025
    • 1.5.3 Blood Sample Testing
    • 1.5.4 Saliva Sample Testing
    • 1.5.5 Cerebrospinal Fluid Testing
    • 1.5.6 Tissue Sample Testing
  • 1.6 Global Neurogenetic Testing Market by Application
    • 1.6.1 Overview: Global Neurogenetic Testing Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospitals
    • 1.6.3 Specialty Clinics
    • 1.6.4 Research Institutes
    • 1.6.5 Diagnostics Laboratories
  • 1.7 Global Neurogenetic Testing Market Size & Forecast
  • 1.8 Global Neurogenetic Testing Market Size and Forecast by Region
    • 1.8.1 Global Neurogenetic Testing Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Neurogenetic Testing Market Size by Region, (2021-2032)
    • 1.8.3 North America Neurogenetic Testing Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Neurogenetic Testing Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Neurogenetic Testing Market Size and Prospect (2021-2032)
    • 1.8.6 South America Neurogenetic Testing Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Neurogenetic Testing Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Quest Diagnostics
    • 2.1.1 Quest Diagnostics Details
    • 2.1.2 Quest Diagnostics Major Business
    • 2.1.3 Quest Diagnostics Neurogenetic Testing Product and Solutions
    • 2.1.4 Quest Diagnostics Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Quest Diagnostics Recent Developments and Future Plans
  • 2.2 Mayo Clinic
    • 2.2.1 Mayo Clinic Details
    • 2.2.2 Mayo Clinic Major Business
    • 2.2.3 Mayo Clinic Neurogenetic Testing Product and Solutions
    • 2.2.4 Mayo Clinic Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Mayo Clinic Recent Developments and Future Plans
  • 2.3 GeneDx
    • 2.3.1 GeneDx Details
    • 2.3.2 GeneDx Major Business
    • 2.3.3 GeneDx Neurogenetic Testing Product and Solutions
    • 2.3.4 GeneDx Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 GeneDx Recent Developments and Future Plans
  • 2.4 Illumina
    • 2.4.1 Illumina Details
    • 2.4.2 Illumina Major Business
    • 2.4.3 Illumina Neurogenetic Testing Product and Solutions
    • 2.4.4 Illumina Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Illumina Recent Developments and Future Plans
  • 2.5 Labcorp (Invitae/MNG Laboratories)
    • 2.5.1 Labcorp (Invitae/MNG Laboratories) Details
    • 2.5.2 Labcorp (Invitae/MNG Laboratories) Major Business
    • 2.5.3 Labcorp (Invitae/MNG Laboratories) Neurogenetic Testing Product and Solutions
    • 2.5.4 Labcorp (Invitae/MNG Laboratories) Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Labcorp (Invitae/MNG Laboratories) Recent Developments and Future Plans
  • 2.6 MedGenome Labs
    • 2.6.1 MedGenome Labs Details
    • 2.6.2 MedGenome Labs Major Business
    • 2.6.3 MedGenome Labs Neurogenetic Testing Product and Solutions
    • 2.6.4 MedGenome Labs Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 MedGenome Labs Recent Developments and Future Plans
  • 2.7 Connecticut Children's
    • 2.7.1 Connecticut Children's Details
    • 2.7.2 Connecticut Children's Major Business
    • 2.7.3 Connecticut Children's Neurogenetic Testing Product and Solutions
    • 2.7.4 Connecticut Children's Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Connecticut Children's Recent Developments and Future Plans
  • 2.8 CENTOGENE
    • 2.8.1 CENTOGENE Details
    • 2.8.2 CENTOGENE Major Business
    • 2.8.3 CENTOGENE Neurogenetic Testing Product and Solutions
    • 2.8.4 CENTOGENE Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 CENTOGENE Recent Developments and Future Plans
  • 2.9 Victorian Clinical Genetics Services
    • 2.9.1 Victorian Clinical Genetics Services Details
    • 2.9.2 Victorian Clinical Genetics Services Major Business
    • 2.9.3 Victorian Clinical Genetics Services Neurogenetic Testing Product and Solutions
    • 2.9.4 Victorian Clinical Genetics Services Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Victorian Clinical Genetics Services Recent Developments and Future Plans
  • 2.10 PacBio
    • 2.10.1 PacBio Details
    • 2.10.2 PacBio Major Business
    • 2.10.3 PacBio Neurogenetic Testing Product and Solutions
    • 2.10.4 PacBio Neurogenetic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 PacBio Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Neurogenetic Testing Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Neurogenetic Testing by Company Revenue
    • 3.2.2 Top 3 Neurogenetic Testing Players Market Share in 2025
    • 3.2.3 Top 6 Neurogenetic Testing Players Market Share in 2025
  • 3.3 Neurogenetic Testing Market: Overall Company Footprint Analysis
    • 3.3.1 Neurogenetic Testing Market: Region Footprint
    • 3.3.2 Neurogenetic Testing Market: Company Product Type Footprint
    • 3.3.3 Neurogenetic Testing Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Neurogenetic Testing Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Neurogenetic Testing Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Neurogenetic Testing Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Neurogenetic Testing Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Neurogenetic Testing Consumption Value by Type (2021-2032)
  • 6.2 North America Neurogenetic Testing Market Size by Application (2021-2032)
  • 6.3 North America Neurogenetic Testing Market Size by Country
    • 6.3.1 North America Neurogenetic Testing Consumption Value by Country (2021-2032)
    • 6.3.2 United States Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Neurogenetic Testing Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Neurogenetic Testing Consumption Value by Type (2021-2032)
  • 7.2 Europe Neurogenetic Testing Consumption Value by Application (2021-2032)
  • 7.3 Europe Neurogenetic Testing Market Size by Country
    • 7.3.1 Europe Neurogenetic Testing Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 7.3.3 France Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Neurogenetic Testing Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Neurogenetic Testing Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Neurogenetic Testing Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Neurogenetic Testing Market Size by Region
    • 8.3.1 Asia-Pacific Neurogenetic Testing Consumption Value by Region (2021-2032)
    • 8.3.2 China Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 8.3.5 India Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Neurogenetic Testing Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Neurogenetic Testing Consumption Value by Type (2021-2032)
  • 9.2 South America Neurogenetic Testing Consumption Value by Application (2021-2032)
  • 9.3 South America Neurogenetic Testing Market Size by Country
    • 9.3.1 South America Neurogenetic Testing Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Neurogenetic Testing Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Neurogenetic Testing Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Neurogenetic Testing Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Neurogenetic Testing Market Size by Country
    • 10.3.1 Middle East & Africa Neurogenetic Testing Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Neurogenetic Testing Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Neurogenetic Testing Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Neurogenetic Testing Market Drivers
  • 11.2 Neurogenetic Testing Market Restraints
  • 11.3 Neurogenetic Testing Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Neurogenetic Testing Industry Chain
  • 12.2 Neurogenetic Testing Upstream Analysis
  • 12.3 Neurogenetic Testing Midstream Analysis
  • 12.4 Neurogenetic Testing Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Neurogenetic Testing market size was valued at US$ 794 million in 2025 and is forecast to a readjusted size of US$ 1683 million by 2032 with a CAGR of 11.4% during review period.
    Neurogenetic testing is a molecular and genomic diagnostic approach used to analyze and interpret genes associated with neurological disorders. This testing helps identify whether an individual carries genetic mutations that may cause neurodegenerative diseases, epilepsy, intellectual disability, autism spectrum disorders, movement disorders, and certain hereditary neuropathies. The value of neurogenetic testing lies not only in early disease screening and clinical diagnosis, but also in guiding physicians to develop personalized treatment plans and assisting families with genetic risk assessment and reproductive planning.
    With the continuous development of gene-targeted drugs, RNA therapy, gene therapy, and personalized treatment plans, accurately identifying a patient's genetic background has become a crucial foundation for formulating treatment strategies. For example, treatment options targeting specific gene defects have emerged for some hereditary neuromuscular diseases, and genetic testing can help doctors screen suitable patients for treatment. Meanwhile, in the field of neurodegenerative diseases, researchers are exploring genetic risk scores (PRS), genetic biomarkers, and disease progression prediction models for early disease identification and patient screening in clinical trials.
    Many childhood neurological diseases, such as intellectual disability, autism spectrum disorder (ASD), developmental delay, and hereditary epilepsy, are closely related to genetic abnormalities. Because these diseases present with complex clinical manifestations, diagnosis based solely on symptoms often presents significant challenges; therefore, genetic testing has become an important tool for improving diagnostic rates. In recent years, an increasing number of medical institutions have begun to adopt genomic testing as a crucial step in assessing complex cases, particularly in newborn screening, diagnosis of rare childhood diseases, and early intervention, leading to a continuously increasing market demand.
    Report Scope
    This report is a detailed and comprehensive analysis for global Neurogenetic Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Neurogenetic Testing market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Neurogenetic Testing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Neurogenetic Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Neurogenetic Testing market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Neurogenetic Testing
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Neurogenetic Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina, Labcorp (Invitae/MNG Laboratories), MedGenome Labs, Connecticut Children's, CENTOGENE, Victorian Clinical Genetics Services, PacBio, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Neurogenetic Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segmentation
    Market segment by Type
    Exome Sequencing
    Whole Genome Sequencing
    RNA Sequencing
    General DNA Testing
    Market segment by Disease Type
    Neurodegenerative Disorders
    Neuromuscular Disorders
    Epilepsy Disorders
    Neurodevelopmental Disorders
    Genetic Brain Disorders
    Market segment by Sample Type
    Blood Sample Testing
    Saliva Sample Testing
    Cerebrospinal Fluid Testing
    Tissue Sample Testing
    Market segment by Application
    Hospitals
    Specialty Clinics
    Research Institutes
    Diagnostics Laboratories
    Market segment by players, this report covers
    Quest Diagnostics
    Mayo Clinic
    GeneDx
    Illumina
    Labcorp (Invitae/MNG Laboratories)
    MedGenome Labs
    Connecticut Children's
    CENTOGENE
    Victorian Clinical Genetics Services
    PacBio
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Neurogenetic Testing product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Neurogenetic Testing, with revenue, gross margin, and global market share of Neurogenetic Testing from 2021 to 2026.
    Chapter 3, the Neurogenetic Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Neurogenetic Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Neurogenetic Testing.
    Chapter 13, to describe Neurogenetic Testing research findings and conclusion.

    Buy now